Researchers at Weizmann Institute of Science, Rehovot, have discovered a unique type of immune cell, the orderly activation of which could be the basis for future treatment of the currently fatal Alzheimer’s disease.
Their findings have led to new concept in how Alzheimer’s is perceived, based on a mechanistic understanding of the central role of microglial cells – the brain’s unique immune cells – in the disease. Prof. Michal Schwartz of the neurobiology department at the institute, said the discovery could eventually lead to new therapy for Alzheimer’s.
Alzheimer’s, the most significant cause of dementia in the elderly population, is a neurodegenerative disorder manifested by various neuronal pathological processes and a significant reduction in brain function.
In the degenerative disease, beta-amyloid protein, or plaques, accumulate within and between brain cells. Due to both structural changes and the weakening of chemical communication pathways, the synapses, or junctions between neuronal cells, are lost. In addition, the cytoskeletal proteins of the axons, or nerve fibers, lose their normal structure, impairing their function and causing massive death of nerve cells.
The brain is a fragile and unique organ that has its own specially tailored immune system separate from the rest of the body. The primary role of the microglia is to recognize, disassemble and dispose of various substances that do not function properly in the brain, from dying cells to various cell debris and protein aggregates. Yet, microglial activity is under tight regulation to allow them to dispose of waste without harming adjacent healthy neurons that retain important information.
The microglia’s activities, from essential immune function to the risk of damaging healthy neurons due to hyperactivity, are well balanced in young healthy individuals, but might become a disadvantage in aging and under certain neuropathological conditions. A key question is why the brain’s own immune cells are not effective in repairing the damage associated with Alzheimer’s disease.
Schwartz has shown over the years that mobilizing cells from the systemic immune system does not always cause harm, and in fact, if well controlled, even help in coping with various brain pathologies. But no one had answered the question whether the microglia are helpful, harmful or useless to the body.
Working together with Prof. Ido Amit of the institute’s immunology department and members of their research groups – postdoctoral researchers Drs. Hadas Keren-Shaul and Assaf Weiner and research students Amit Spinrad, Orit Matcovitch-Natan and Raz Dvir-Szternfeld – Schwartz has now provided an answer to this question, along with a new research approach toward finding ways of treating the disease.
They studied a genetically engineered mouse model of Alzheimer’s, whose genetic makeup includes five mutant human genes that cause an aggressive form of the disease. The brains of these mice exhibit features similar to those that take place in the brains of humans suffering from the dementia.
A significant barrier to understanding the roles of immune cells in Alzheimer’s and other neurodegenerative diseases is the ability to accurately distinguish between similar cells with different functions, and thus understand which is “friend” and which is “foe.”
The team employed advanced single-cell genomic sequencing technology – a “genetic microscope” developed in Amit’s lab in recent years – to fully sequence the genetic material of single cells, allowing them to identify the unique function of these immune cells, even when they are extremely rare.
In this study, they sequenced the RNA content of all the immune cells in the brains of the Alzheimer’s disease mouse model and repeated this experiment at different points in the disease progression and compared the results with those from healthy mice.
Credit: Jerusalem Post
For questions on how Alzheimer’s disease affects your estate planning, contact Mina Sirkin, Probate Attorney.
